Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 29Rituximab 25fludarabine 15fludarabine phosphate 13Specimen Handling 12obinutuzumab 10ibrutinib 10Magnetic Resonance Spectroscopy 10Prednisone 9Doxorubicin 9Mycophenolic Acid 8Etoposide 8tocilizumab 7polatuzumab vedotin 7X-Rays 7Whole-Body Irradiation 7Phantoms, Imaging 7Lenalidomide 7Biopsy 7glofitamab 6Vincristine 6Melphalan 6Busulfan 6Bendamustine Hydrochloride 6venetoclax 5pirtobrutinib 5acalabrutinib 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Nivolumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × EPOCH protocol × 90 days × Clear all
NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
132 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡